{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/breast-cancer-managing-fh/management/breast-cancer-managing-fh/","result":{"pageContext":{"chapter":{"id":"b118c829-c5a1-5ee5-a8da-71eb67facd8d","slug":"breast-cancer-managing-fh","fullItemName":"Scenario: Breast cancer - managing FH","depth":2,"htmlHeader":"<!-- begin field f5bc8b0e-b4cb-4118-bb11-a58c2c073157 --><h2>Scenario: Breast cancer - managing family history</h2><!-- end field f5bc8b0e-b4cb-4118-bb11-a58c2c073157 -->","summary":"Covers the primary care management of women and men who are concerned that their family history indicates an increased risk of breast cancer.","htmlStringContent":"<!-- begin item 71a89233-6637-40b3-84b2-57b88d4a4ec8 --><!-- begin field 3fc841b0-0cec-41a0-a05c-acbc01582bbd --><p>From age 16 years onwards.</p><!-- end field 3fc841b0-0cec-41a0-a05c-acbc01582bbd --><!-- end item 71a89233-6637-40b3-84b2-57b88d4a4ec8 -->","topic":{"id":"273ad47e-ae65-5768-be53-5ddd1a59479e","topicId":"bd5ef0a7-5bdf-453b-919f-23ebeade59e8","topicName":"Breast cancer - managing FH","slug":"breast-cancer-managing-fh","lastRevised":"Last revised in December 2018","chapters":[{"id":"f6ca27fc-9049-5932-b6b5-c6a1a14a77fd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2dd4a7a9-b879-5145-a15c-5922ac8e62ed","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1eedf81f-6c36-5c24-816f-0c373b4fe0f4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f7449f3e-937f-584a-90af-48470e794a2c","slug":"changes","fullItemName":"Changes"},{"id":"28bea84b-3026-59d1-a564-3b8f8e660f19","slug":"update","fullItemName":"Update"}]},{"id":"d2268871-af9e-569e-ae6e-a786ab1bacec","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c2ad0bbf-95fa-5512-a763-618d653b1f5e","slug":"goals","fullItemName":"Goals"},{"id":"b4ec1615-f118-573f-a98d-d4bbfdf7d53d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"467c7316-a736-5600-b8e5-1c4ebf44b7ce","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"34c8a1ea-20f5-5197-86ff-6e75ed2a01c5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3361517e-9866-5a17-aabf-4d923a96c917","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"fdcd7c54-3a68-5903-a4a1-241a63d19e62","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d7bd1803-d45e-508d-8661-62ebaa4b3353","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6831679-919f-5e59-b6b9-d09ed6486aca","slug":"definition","fullItemName":"Definition"},{"id":"7d6fa54b-1dc8-5cbd-9bf4-6d9ac0dc26f0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c5d1b518-b87d-58d6-8554-f3960af8f976","slug":"genetic-risk-factors","fullItemName":"Genetic risk factors"}]},{"id":"61970169-7827-5d9e-acb0-e40e0888525d","fullItemName":"Management","slug":"management","subChapters":[{"id":"b118c829-c5a1-5ee5-a8da-71eb67facd8d","slug":"breast-cancer-managing-fh","fullItemName":"Scenario: Breast cancer - managing FH"}]},{"id":"eaf7a93e-8dae-5737-ba9c-13e8ad484b3c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a9d84940-3c17-5039-b3f8-73ef73f06d13","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a8dea3b7-f328-50ea-985f-2d54f906032c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"067fe34b-66c2-52be-b2a6-f9366eaa8c2e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1f91e5ff-a2aa-5aaf-ac5c-67750822d1e8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0bfaeb6f-e800-5a87-a861-0d00aeb7c136","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"773a3929-781a-5faf-8d55-166112725d3a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"89bfc412-56d8-52c5-95b1-6e923396679a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"61970169-7827-5d9e-acb0-e40e0888525d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"0e5bd9e0-3aba-5fa5-9e07-ab4595605f63","slug":"taking-the-family-history","fullItemName":"Taking the family history","depth":3,"htmlHeader":"<!-- begin field 13177738-5fab-4c3d-aefc-7e51aeb4ed7c --><h3>When and how should I take a family history?</h3><!-- end field 13177738-5fab-4c3d-aefc-7e51aeb4ed7c -->","summary":null,"htmlStringContent":"<!-- begin item c6ff6212-0462-4ef7-b487-623369f057e2 --><!-- begin field dcbe536b-0f67-4a65-8201-233ae0973127 --><ul><li><strong>Take a family history of breast cancer when:</strong><ul><li>A person has concerns about their family history of breast cancer.</li><li>A person has breast symptoms.</li><li>It is clinically relevant, for example:<ul><li>In women over 35 years of age using an oral contraceptive pill.</li><li>In women being considered for long-term hormone replacement therapy (HRT).</li></ul></li></ul></li><li><strong>Document a family tree including the person and their first-degree relatives (mother, father, daughter, son, sister, and brother) and second-degree relatives (grandparents, grandchildren, aunt, uncle, niece, nephew, half-sister, and half-brother).</strong><ul><li>Ask about:<ul><li>All cancer diagnoses (including breast cancer).</li><li>People in whom a <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/background-information/genetic-risk-factors/\">faulty gene</a> (such as BRCA1, BRCA2, or TP53) has been identified.</li><li>Age at diagnosis.</li><li>Presence of bilateral disease.</li><li>Male breast cancer.</li><li>Multiple cases in the family (particularly on one side).</li><li>Jewish ancestry.</li><li>Other related early onset tumours, such as ovarian, pancreatic, and prostate cancer, sarcoma, glioma, and adrenal carcinoma.</li></ul></li></ul></li></ul><!-- end field dcbe536b-0f67-4a65-8201-233ae0973127 --><!-- end item c6ff6212-0462-4ef7-b487-623369f057e2 -->","subChapters":[{"id":"8aa92deb-10e1-52b4-aa84-f08e05e9c932","slug":"basis-for-recommendation-ca5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c12eeb22-baa2-4628-b8fc-2fab108526a5 --><h4>Basis for recommendation</h4><!-- end field c12eeb22-baa2-4628-b8fc-2fab108526a5 -->","summary":null,"htmlStringContent":"<!-- begin item ca5cf3af-79fa-4d37-8264-fef027a4d1ca --><!-- begin field b1eaf2db-02f6-41f9-ac2a-fe1ab7bb18f1 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer </em>(full NICE guideline)<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>] and <em>Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">NICE, 2017</a>]. </p><h5>When to take a family history for breast cancer</h5><ul><li>NICE recommends that if a person has breast symptoms or has concerns about relatives with breast cancer, a first- and second-degree family history should be taken in primary care. A family history allows a classification of risk to be made that will direct further management decisions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">NICE, 2017</a>].</li><li>NICE found<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>]:<ul><li>Four observational studies that assessed the accuracy of the family history provided by women (735 women with breast cancer and 251 women without breast cancer) and concluded that family histories were generally reliable.</li><li>A review of five case studies that showed the importance of verifying the history.</li><li>One longitudinal, qualitative study of 46 women attending a UK genetics clinic for familial breast/ovarian cancer which found that poor communication between family members may impede the collection of family history.</li></ul></li></ul><h5>Criteria used to determine risk of breast cancer</h5><ul><li>NICE reviewed the evidence for risk factors for breast cancer, including evidence from epidemiological studies, and concluded that<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>]:<ul><li>The risk of breast cancer in women with an affected first-degree relative is approximately twice the risk in other women.</li><li>The risk of breast cancer increases with the number of affected relatives, and increases as the age of those affected decreases. Only a minority of this increase in risk is due to the presence of gene mutations, such as BRCA1, BRCA2, or TP53.</li><li>The presence of other malignancies (such as ovarian, prostate, pancreatic cancer) or male breast cancer in a family in addition to female breast cancer increases the likelihood of having a BRCA1/2 mutation.</li><li>The presence of early-onset sarcoma and childhood cancers, such as adrenal carcinoma, increases the likelihood of having a TP53 mutation.</li></ul></li></ul><!-- end field b1eaf2db-02f6-41f9-ac2a-fe1ab7bb18f1 --><!-- end item ca5cf3af-79fa-4d37-8264-fef027a4d1ca -->","subChapters":[]}]},{"id":"52ac9301-fa43-5a2e-af56-60d5540167e1","slug":"who-to-refer","fullItemName":"Who to refer","depth":3,"htmlHeader":"<!-- begin field 9fab48f1-5655-45be-baea-27f354695155 --><h3>How do I assess a woman's risk of breast cancer and need for referral?</h3><!-- end field 9fab48f1-5655-45be-baea-27f354695155 -->","summary":null,"htmlStringContent":"<!-- begin item 591315b3-50ad-4638-aa58-c51c84b537b9 --><!-- begin field 83fb6bf8-cfaf-4313-95f0-e463687e5e3c --><ul><li><strong>People <em>without</em> a personal history of breast cancer can be managed in primary care if they have only one first-degree relative (mother, father, daughter, son, sister, or brother) or second-degree relative (grandparents, grandchildren, aunt, uncle, niece, nephew, half-sister, or half-brother) diagnosed with breast cancer when over 40 years of age, provided that none of the following are present in the family history:</strong><ul><li>Bilateral breast cancer.</li><li>Male breast cancer.</li><li>Ovarian cancer.</li><li>Jewish ancestry.</li><li>Sarcoma in a relative younger than 45 years of age.</li><li>Glioma or childhood adrenal cortical carcinomas.</li><li>Complicated patterns of multiple cancers at a young age.</li><li>Two or more relatives with breast cancer on the father's side of the family.</li></ul></li><li><strong>Offer referral to secondary care to people </strong><strong>without a personal history of breast cancer </strong><strong>who have any of the following:</strong><ul><li>One first-degree female relative diagnosed with breast cancer under the age of 40 years.</li><li>One first-degree male relative diagnosed with breast cancer at any age.</li><li>One first-degree relative with bilateral breast cancer where the first primary was diagnosed under the age of 50 years.</li><li>Two first-degree relatives, or one first-degree and<em> </em>one second-degree relative, diagnosed with breast cancer at any age.</li><li>One first-degree or second-degree relative diagnosed with breast cancer at any age and<em> </em>one first-degree or second-degree relative diagnosed with ovarian cancer at any age (one of these should be a first-degree relative).</li><li>Three first-degree or second-degree relatives diagnosed with breast cancer at any age.</li></ul></li><li><strong>Seek specialist advice from secondary care or a specialist genetics service if:</strong><ul><li>Any of the following are present in the family history in addition to breast cancers in relatives not fulfilling the above criteria:<ul><li>Bilateral breast cancer.</li><li>Male breast cancer.</li><li>Ovarian cancer.</li><li>Jewish ancestry.</li><li>Sarcoma in a relative younger than 45 years of age.</li><li>Glioma or childhood adrenal cortical carcinomas.</li><li>Complicated patterns of multiple cancers at a young age.</li><li>Two or more relatives with breast cancer on the father's side of the family.</li></ul></li><li>There is uncertainty about whether or not to refer.</li><li>The person is not sufficiently reassured by the information provided.</li></ul></li><li><strong>Refer directly to a specialist genetics service</strong> if a high-risk predisposing <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/background-information/genetic-risk-factors/\">gene mutation</a> (such as BRCA1, BRCA2, or TP53) has been identified.</li><li><strong>Give appropriate <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/management/breast-cancer-managing-fh/#information-support\">information and support</a>.</strong></li></ul><!-- end field 83fb6bf8-cfaf-4313-95f0-e463687e5e3c --><!-- end item 591315b3-50ad-4638-aa58-c51c84b537b9 -->","subChapters":[{"id":"674f4214-ceda-5596-91bd-ec249febf122","slug":"basis-for-recommendation-47e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ace7f5d2-04b0-4382-a7f7-150e334b1390 --><h4>Basis for recommendation</h4><!-- end field ace7f5d2-04b0-4382-a7f7-150e334b1390 -->","summary":null,"htmlStringContent":"<!-- begin item 47e27e8c-0dab-4d4a-922c-d351bafef448 --><!-- begin field 522c97c8-0978-43a8-b33d-910f41741139 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer </em>(full NICE guideline) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>] and <em>Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">NICE, 2017</a>]. </p><ul><li>NICE reviewed the evidence for risk factors for breast cancer, including evidence from epidemiological studies, and concluded that:<ul><li>Women with an affected first-degree relative have approximately twice the risk of breast cancer compared with other women.</li><li>The risk of breast cancer increases with the number of affected relatives, and increases as the age of those affected decreases. Only a minority of this increase in risk is due to the presence of gene mutations, such as BRCA1, BRCA2, or TP53.</li><li>The presence of other malignancies (such as ovarian, prostate, pancreatic cancer) or male breast cancer in a family in addition to female breast cancer increases the likelihood of having a BRCA1 or BRCA2 mutation.</li><li>The presence of early-onset sarcoma and childhood cancers, such as adrenal carcinoma, increases the likelihood of having a TP53 mutation.</li></ul></li><li>The Ashkenazi Jewish community has three founder mutations, two in BRCA1 and one in BRCA2, which account for most of the inherited cancer risk due to BRCA1 and BRCA2 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Gabai-Kapara, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Paluch-Shimon, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>]. In this population, 2.5% of people carry one of these three mutations, which account for 11% of breast cancer and 40% of ovarian cancer cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Gabai-Kapara, 2014</a>].</li></ul><!-- end field 522c97c8-0978-43a8-b33d-910f41741139 --><!-- end item 47e27e8c-0dab-4d4a-922c-d351bafef448 -->","subChapters":[]}]},{"id":"1dad9ce9-d3bb-54f4-8b59-0ab692e618ff","slug":"information-support","fullItemName":"Information and support","depth":3,"htmlHeader":"<!-- begin field 07da0253-57f4-4653-8447-a9ba0089aee0 --><h3>What information and support should I provide?</h3><!-- end field 07da0253-57f4-4653-8447-a9ba0089aee0 -->","summary":null,"htmlStringContent":"<!-- begin item 6a456ed0-b462-468e-9f99-a9ba0089ad91 --><!-- begin field 850010cb-43ea-4858-a879-a9ba0089aee0 --><ul><li><strong>For all people:</strong><ul><li>Provide information on breast cancer risk, including information on <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/background-information/definition/\">family history</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/background-information/genetic-risk-factors/\">genetic risk factors</a>.<ul><li>The leaflet <a data-hyperlink-id=\"2a992cca-51e2-456b-b3b4-a9c30169359f\" href=\"https://www.breastcancercare.org.uk/sites/default/files/publications/pdf/bcc32_breast_cancer_in_families_web_pdf.pdf\">Family history, genes and breast cancer</a> published by Breast Cancer Care (<a data-hyperlink-id=\"58c0945f-04ad-40bd-b393-a9c3016935ce\" href=\"https://www.breastcancercare.org.uk/\">www.breastcancercare.org.uk</a>) explains how family history can affect breast cancer risk. It includes information on how risk is assessed, the options for managing risk, and genetic testing.</li></ul></li><li>Explain the principles of breast awareness.<ul><li>This is a process whereby the person becomes familiar with their own breasts by looking and feeling and reporting promptly any changes, such as discomfort or pain; lumps, thickening, or bumpy areas; nipple changes or discharge; or changes in the appearance of the breast, such as in the shape or the presence of dimpling of the skin.</li><li>The leaflet <a data-hyperlink-id=\"31c3375c-faee-4d94-adcb-a9b900d42449\" href=\"https://www.gov.uk/government/publications/nhs-breast-screening-awareness-leaflet\">Be breast aware</a> published by Public Health England (PHE, <a data-hyperlink-id=\"3bec764e-f478-4986-9659-a9b900d42457\" href=\"https://www.gov.uk/\">www.gov.uk</a>) can be used by healthcare professionals to explain to women how to be aware of changes in their breasts. </li></ul></li><li>Give lifestyle advice regarding breast cancer risk.<ul><li>Advise on reduction of alcohol intake, maintenance of a healthy weight, increasing physical exercise, and smoking cessation (where appropriate).</li><li>Advise women that the following may reduce the risk of breast cancer: having a first child at a younger age, having a large family, and breastfeeding.</li><li>Give women appropriate information on <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/management/breast-cancer-managing-fh/#advice-on-hormonal-contraception\">oral contraceptives</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/management/breast-cancer-managing-fh/#advice-on-hormone-replacement-therapy\">hormone replacement therapy</a>.</li></ul></li><li>Provide details for sources of support and information, including local and national support groups. <ul><li><a data-hyperlink-id=\"25bb0412-84e5-43da-9cda-a9c30158e239\" href=\"http://www.breastcancergenetics.co.uk/\">The National Hereditary Breast Cancer Helpline</a> (01629 813000, available 8am–10pm) provides help and information to those concerned about their family history of breast cancer.</li><li><a data-hyperlink-id=\"3b7417d0-ab57-44a2-a124-a9c30158e46a\" href=\"https://www.cancerresearchuk.org/about-us\">Cancer Research UK</a> provides cancer information to the public, including <a data-hyperlink-id=\"8b5e6e81-7d1e-4fa9-9ab9-a9c30158e497\" href=\"https://publications.cancerresearchuk.org/patient-services?filter_numberperpage=-1\">leaflets</a> on prevention, diagnosis, and understanding cancer and information on <a data-hyperlink-id=\"911a0698-3778-4cd3-b980-a9c301656adc\" href=\"https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/resources-books\">breast cancer and general support organizations</a>.</li><li><a data-hyperlink-id=\"25c18246-6f73-4fd6-9bd9-a9c30158e530\" href=\"http://www.cancernet.co.uk/supportgroups.htm\">CancerNetUK</a> provides information and links to various cancer support groups throughout the UK as well as other European and English speaking countries. </li></ul></li><li>Provide other useful advice and information, for example:<ul><li>Advise that they can bring a family member/ friend with them to appointments.</li><li>Provide details of any trials or studies that may be appropriate.</li></ul></li></ul></li><li><strong>For people who are being referred to secondary care or a specialist genetic clinic, </strong>also provide information on:<ul><li>The risk assessment exercise that will take place. Advise the person on how to obtain a comprehensive family history if required.</li><li>Potential outcomes, depending on the outcome of the risk assessment (including referral back to primary care, management within secondary care, or referral to a specialist genetics service) and what may happen at each level.</li></ul></li><li><strong>For people who are not being referred,</strong> also advise that they should come for review with their GP if:<ul><li>There is a change in family history (as their risk of breast cancer may have altered).</li><li>Breast symptoms develop.</li></ul></li><li><strong>Encourage attendance at the local NHS Breast Screening Programme for women 50 years of age and older.</strong><ul><li>The NHS Breast Screening Programme is a rolling scheme which invites women aged 50–70 years in England, Northern Ireland, Scotland, and Wales who are registered with a GP for a routine mammogram every three years.  Women at increased risk of breast cancer (for example those with a strong family history) may be eligible for breast screening before 50 years of age.</li><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/breast-screening/\">Breast screening</a>.</li></ul></li></ul><!-- end field 850010cb-43ea-4858-a879-a9ba0089aee0 --><!-- end item 6a456ed0-b462-468e-9f99-a9ba0089ad91 -->","subChapters":[{"id":"23c42cd0-322d-593e-8ca0-a561404d9aa9","slug":"basis-for-recommendation-72e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4deae120-98b6-4bf9-a7b7-a9ba0089aeee --><h4>Basis for recommendation</h4><!-- end field 4deae120-98b6-4bf9-a7b7-a9ba0089aeee -->","summary":null,"htmlStringContent":"<!-- begin item 72ee9cf7-52ad-4bc7-bd22-a9ba0089aeee --><!-- begin field 38777ade-a80b-47dc-a16e-a9ba0089aeee --><h5>Explaining the principles of breast awareness</h5><ul><li>Evidence from a Cochrane systemtic review (search date: October 2007) did not suggest a beneficial effect of breast screening by either self-examination or clinical examination, but suggested increased harms in terms of increased numbers of benign lesions identified and an increased number of biopsies performed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Kosters and Gotsche, 2003</a>]. </li><li>However, there is a consensus among cancer geneticists supporting its use to help early detection in women who are at increased risk because of a family history of breast cancer.</li></ul><h5>Measures to reduce the risk of breast cancer</h5><ul><li><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guidelines <em>Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer </em>(full NICE guideline)<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>] and <em>Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">NICE, 2017</a>]. </p><ul><li><strong>Alcohol</strong><ul><li>NICE examined five meta-analyses, one systematic review, and one cohort study and concluded that there is no good evidence to suggest that the risk from drinking alcohol is any different for women with a family history of breast cancer compared with women as a whole. Women who drink a moderate amount of alcohol have a slightly higher risk of breast cancer than those who abstain.</li><li>A subsequent case-controlled study investigated women with BRCA1 or BRCA2 mutations who had a history of breast cancer (cases [n = 195 and 128, respectively]) or did not have a history of breast cancer (controls [n = 302 and 179, respectively]) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">McGuire et al, 2006</a>]. No positive association was found between alcohol intake and the risk of breast cancer in women with either BRCA1 or BRCA2 mutations.</li></ul></li><li><strong>Weight</strong><ul><li>NICE found evidence that a high body mass index is associated with a clinically significant increase in postmenopausal breast cancer risk in the general population.</li></ul></li><li><strong>Physical activity</strong><ul><li>NICE reviewed the evidence and concluded that moderate physical exercise is associated with a decreased risk of breast cancer in the general population.</li></ul></li><li><strong>Smoking cessation</strong><ul><li>NICE found conflicting evidence for an association between smoking and breast cancer but advises that women should be advised not to smoke, in line with current health advice.</li></ul></li><li><strong>Menstrual/reproductive factors</strong><ul><li>After reviewing the available limited evidence, NICE concluded that the risk of breast cancer is:<ul><li>Increased by a late menopause (55 years of age or older), older age at first birth, and early menarche.</li><li>Decreased by pregnancy, with increasing numbers of pregnancies conferring greater risk reduction.</li></ul></li><li>However, in women who carry mutations in BRCA1 or BRCA2:<ul><li>An analysis of data from a cohort study of 1601 women (1187 with a BRCA1 mutation and 414 women with a BRCA2 mutation) found no association between the age of either the menarche or the menopause on breast cancer risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Chang-Claude et al, 2007</a>].</li><li>There is conflicting evidence about whether younger age at first birth alters the risk of breast cancer, but there is evidence that increased parity offers protection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Andrieu et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Antoniou et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Kotsopoulos et al, 2007</a>].</li></ul></li></ul></li><li><strong>Breastfeeding</strong><ul><li>After reviewing the available evidence (one meta-analysis, one systematic review, and a collaborative group re-analysis of individual data from 47 epidemiological studies), NICE concluded that breastfeeding confers a small protective effect on the risk of breast cancer.</li></ul></li></ul></li><li>According to <a data-hyperlink-id=\"057cf2e2-a064-4446-bc5a-a9c3017a9372\" href=\"https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/risk-factors\">Cancer Research UK</a> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Cancer Research UK, 2018a</a>]:<ul><li>Alcohol drinking causes 8% of breast cancer cases in the UK.</li><li>Overweight and obesity cause 8% of breast cancer cases in the UK.</li><li>Breast cancer risk is 13–25% lower in the most active (including recreational and household activity) women compared with the least active women. Breast cancer risk decreases by 5% for every 2 hours per week increment in recreational activity (moderate and vigorous). Light-intensity activity may be insufficient to reduce breast cancer risk.</li><li>Breast cancer risk is 7–13% higher in current smokers, and 6–9% higher in former smokers, compared with people who have never smoked; however, confounding by alcohol is possible. Breast cancer risk among BRCA1 mutation carriers is not associated with smoking, but breast cancer risk among BRCA2 mutation carriers is higher in people who smoke.</li><li>Post-menopausal hormones cause 2% of breast cancer cases in the UK.</li><li>Not breastfeeding causes 5% of breast cancer cases in the UK.</li><li>Oral contraceptives cause fewer than 1% of breast cancer cases in the UK.</li></ul></li></ul><h5>Breast screening</h5><ul><li>For detailed information and evidence behind the NHS Breast Screening Programme, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/breast-screening/\">Breast screening</a>.</li></ul><!-- end field 38777ade-a80b-47dc-a16e-a9ba0089aeee --><!-- end item 72ee9cf7-52ad-4bc7-bd22-a9ba0089aeee -->","subChapters":[]}]},{"id":"7afbc062-a67e-5147-9cc6-66c611c26e9e","slug":"advice-on-hormonal-contraception","fullItemName":"Advice on hormonal contraception","depth":3,"htmlHeader":"<!-- begin field e11c61a1-08a7-4971-915e-d93d520f5977 --><h3>Which hormonal contraception can be considered?</h3><!-- end field e11c61a1-08a7-4971-915e-d93d520f5977 -->","summary":null,"htmlStringContent":"<!-- begin item 2c359528-6ae0-40bf-9560-65e01ef0d2fe --><!-- begin field 7e73314f-50af-4f3b-b4c1-7871f812f980 --><ul><li><strong>For women with a family history of breast cancer,</strong> <strong>the following may, therefore, be used without restriction (UKMEC category 1):</strong><ul><li>The copper-bearing intrauterine device (Cu-IUD). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/\">Contraception - IUS/IUD</a>.</li><li>The levonorgestrel-releasing intrauterine system (LNG-IUS, for example, Mirena<sup>®</sup>). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/\">Contraception - IUS/IUD</a>.</li><li>Etonogestrel-only implant (Nexplanon<sup>®</sup>). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a><hyperlink-marker innertext=\"Contraception - progestogen-only methods\" refid=\"-489678\"></hyperlink-marker>.</li><li>Depot medroxyprogesterone acetate (Depo-Provera<sup>®</sup>, SAYANA PRESS<sup>®</sup>). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a><hyperlink-marker innertext=\"Contraception - progestogen-only methods\" refid=\"-489678\"></hyperlink-marker>.</li><li>Progestogen-only pill (POP). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a><hyperlink-marker innertext=\"Contraception - progestogen-only methods\" refid=\"-489678\"></hyperlink-marker>.</li><li>Combined hormonal contraceptives (CHC). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>.<ul><li>Inform women aged over 35 years with a family history of breast cancer that there is an increased risk of breast cancer associated with taking the oral contraceptive pill, given that their absolute risk increases with age. </li><li>Advice to women up to age 35 years with a family history of breast cancer should be in keeping with general health advice on the use of the oral contraceptive pill. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/\">Combined oral contraceptives</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>.</li></ul></li></ul></li><li><strong>For women who are known carriers of a gene mutation associated with breast cancer (such as BRCA1 or BRCA2):</strong><ul><li>The Cu-IUD may be used without restriction (UKMEC category 1).</li><li>The following methods may be generally used (UKMEC category 2):<ul><li>POP.</li><li>Depot medroxyprogesterone acetate (Depot-Provera<sup>®</sup>, SAYANA PRESS<sup>®</sup>).</li><li>Etonogestrel-only implant (Nexplanon<sup>®</sup>).</li><li>LNG-IUS.</li></ul></li><li>If the CHC is being considered (UKMEC category 3), discuss with (or refer the woman to) a specialist genetics service, as views are conflicting on whether or not the protective effects of CHC against ovarian cancer outweigh the increased risk of breast cancer.  </li></ul></li></ul><!-- end field 7e73314f-50af-4f3b-b4c1-7871f812f980 --><!-- end item 2c359528-6ae0-40bf-9560-65e01ef0d2fe -->","subChapters":[{"id":"ac87253f-7285-5a78-9d03-20b37d07aeed","slug":"basis-for-recommendation-861","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3500cb6d-c725-40da-bcac-a34753712898 --><h4>Basis for recommendation</h4><!-- end field 3500cb6d-c725-40da-bcac-a34753712898 -->","summary":null,"htmlStringContent":"<!-- begin item 861bd77d-2440-4f62-87f3-7bec86589000 --><!-- begin field 8c4f3e16-7c91-4f25-9632-f826cf3c8f8a --><p>These recommendations are based largely on the Faculty of Sexual and Reproductive Healthcare (FSRH) <em>UK Medical Eligibility Criteria (UKMEC) for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">FSRH, 2016</a>] and the National Institute for Health and Care Excellence (NICE) guidelines <em>Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer </em>(full NICE guideline)<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>] and <em>Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">NICE, 2017</a>]. </p><h5>Women with a family history of breast cancer who are not known to be carriers of a gene mutation</h5><ul><li>The UKMEC for contraceptive use states that a family history of breast cancer is not a contraindication to any form of hormonal contraception or intrauterine device (UKMEC category 1: a condition for which there is no restriction for the use of the contraceptive method) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">FSRH, 2016</a>].</li><li>NICE found consistent evidence from three meta-analyses of case-control and cohort studies, plus one large case-controlled study (4575 women with breast cancer and 4682 women without breast cancer) that the effect of oral contraception on breast cancer risk is similar in women with or without a family history of breast cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>]. However, NICE advises that women aged over 35 years with a family history of breast cancer should be informed of an increased risk of breast cancer associated with taking the oral contraceptive pill, given that their absolute risk increases with age. </li></ul><h5>Women who are known carriers of a gene mutation associated with an increased risk of breast cancer</h5><ul><li>According to the UKMEC for contraceptive use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">FSRH, 2016</a>]:<ul><li>There is no restriction for the use of the copper intrauterine device (UKMEC category 1: a condition for which there is no restriction for the use of the contraceptive method).</li><li>The benefits generally outweigh the risks for the use of the levonorgestrel intrauterine device, the progestogen-only pill, depot medroxyprogesterone acetate, and the etonogestrel-only implant (UKMEC category 2: a condition for which the advantages of using the method generally outweigh the theoretical or proven risks).</li><li>The use of a combined hormonal contraceptive (CHC) is classified as UKMEC category 3: a condition where the theoretical or proven risks usually outweigh the advantages of using the method. The provision of a method requires expert clinical judgement and/or referral to a specialist contraceptive provider, since use of the method is not usually recommended unless other more appropriate methods are not available or not acceptable.</li></ul></li><li>Evidence from one case-control study showed that ever use of oral contraceptives was associated with a 20% increase in breast cancer risk in women who had a BRCA1 mutation, but BRCA2 mutation carriers were not found to be at increased risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>]. <ul><li>NICE advises that for women with BRCA1 mutations, the conflicting effects of a possible increased risk of breast cancer under the age of 40 years and the lifetime protection against ovarian cancer risk from taking the oral contraceptive pill should be discussed<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">NICE, 2017</a>].</li><li>The recommendation to refer the woman to a specialist genetic service to discuss use of a CHC is based on advice from the Northern Genetics Service, as opinions are divided on whether or not the reduction in risk of ovarian cancer outweighs the increase in risk of breast cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Newcastle upon Tyne Hospitals NHS Foundation Trust, 2013</a>]. </li></ul></li></ul><!-- end field 8c4f3e16-7c91-4f25-9632-f826cf3c8f8a --><!-- end item 861bd77d-2440-4f62-87f3-7bec86589000 -->","subChapters":[]}]},{"id":"96874624-4f73-598b-92b7-3b2264cd6cd5","slug":"advice-on-hormone-replacement-therapy","fullItemName":"Advice on hormone replacement therapy","depth":3,"htmlHeader":"<!-- begin field a6e4ac6d-644c-4e0a-b16f-4848d47b7d5a --><h3>How should I manage a woman with a family history of breast cancer who wishes to take hormone replacement therapy?</h3><!-- end field a6e4ac6d-644c-4e0a-b16f-4848d47b7d5a -->","summary":null,"htmlStringContent":"<!-- begin item 08c49906-9b51-4e48-b728-e051742a01a2 --><!-- begin field 453d6654-6024-4515-913d-9b75c3a27f1d --><ul><li><strong>If the woman is at low risk of breast cancer </strong>(that is, she does not fulfil the referral <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/management/breast-cancer-managing-fh/#who-to-refer\">criteria</a> to secondary care), hormone replacement therapy (HRT) may be prescribed. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a>.</li><li><strong>If the woman is at increased risk of breast cancer </strong>(that is, she fulfils the referral <a class=\"topic-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/management/breast-cancer-managing-fh/#who-to-refer\">criteria</a> to secondary care):<ul><li>Ensure that she has been referred to secondary care for assessment of her breast cancer risk.</li><li>Inform her of the increase in breast cancer risk with type and duration of HRT, and refer her to secondary care for advice as to whether or not it is appropriate to prescribe HRT.</li><li>Provide information on non-hormonal and non-pharmacological treatments, such as antidepressants (selective serotonin reuptake inhibitor), vaginal moisturisers and lubricants, cognitive behavioural therapy (CBT), hypnosis, acupuncture, and relaxation techniques, for the management of symptoms. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#non-hormonal-treatments\">Managing the menopause without HRT</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a>.</li></ul></li></ul><!-- end field 453d6654-6024-4515-913d-9b75c3a27f1d --><!-- end item 08c49906-9b51-4e48-b728-e051742a01a2 -->","subChapters":[{"id":"3d898e94-9ae2-5760-9a4d-15c3930d6477","slug":"basis-for-recommendation-ec5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7514ae02-5486-4b06-8187-38c3f69ed031 --><h4>Basis for recommendation</h4><!-- end field 7514ae02-5486-4b06-8187-38c3f69ed031 -->","summary":null,"htmlStringContent":"<!-- begin item ec553e74-3a7b-4f20-ac53-f591b73615f0 --><!-- begin field 3a39a7ab-9bf4-4661-a868-c14fa1a6c3ce --><h5>Managing women at low risk of breast cancer</h5><ul><li>The basis for recommending hormone replacement therapy (HRT) in women at low risk of breast cancer, and the evidence for the benefits and risks associated with its use, can be found in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a>.</li></ul><h5>Managing women at increased risk of breast cancer</h5><ul><li>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guidelines <em>Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer </em>(full NICE guideline)<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">National Collaborating Centre for Cancer, 2017</a>] and <em>Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">NICE, 2017</a>].<ul><li>NICE advises that women with a family history of breast cancer who are considering taking, or already taking, HRT should be informed of the increase in breast cancer risk with type and duration of HRT. This recommendation is based on evidence from several studies, including a review of 51 epidemiological studies carried out in 21 countries, mainly North America and Europe, (n = 52,705 women with breast cancer and 108,411 women without breast cancer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Collaborative Group on Hormonal Factors in Breast Cancer, 1997</a>] and a prospective cohort study (the Million Women Study) which looked at the effects of HRT on the incidence of, and mortality from, breast cancer (n = 1,084,110 women aged 50–64 years) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Million Women Study Collaborators, 2003</a>].</li></ul></li><li>CKS recommends seeking specialist advice about prescribing HRT to women who are at increased risk of breast cancer because the risks associated with HRT vary depending on the individual and require expertise to make an informed decision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-cancer-managing-fh/references/\">Rees, 2009</a>].</li></ul><!-- end field 3a39a7ab-9bf4-4661-a868-c14fa1a6c3ce --><!-- end item ec553e74-3a7b-4f20-ac53-f591b73615f0 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}